Signition LP acquired a new stake in ImmunoGen, Inc. (NASDAQ:IMGN) during the third quarter, Holdings Channel reports. The institutional investor acquired 12,115 shares of the biotechnology company’s stock, valued at approximately $115,000.
Several other hedge funds have also recently added to or reduced their stakes in the business. Public Employees Retirement Association of Colorado purchased a new position in shares of ImmunoGen in the third quarter valued at about $185,000. Assenagon Asset Management S.A. purchased a new position in shares of ImmunoGen in the third quarter valued at about $579,000. Alps Advisors Inc. increased its position in shares of ImmunoGen by 36.6% in the third quarter. Alps Advisors Inc. now owns 263,711 shares of the biotechnology company’s stock valued at $2,497,000 after acquiring an additional 70,640 shares during the period. Essex Investment Management Co. LLC purchased a new position in shares of ImmunoGen in the third quarter valued at about $584,000. Finally, United Services Automobile Association increased its position in shares of ImmunoGen by 39.1% in the second quarter. United Services Automobile Association now owns 22,945 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 6,455 shares during the period. Hedge funds and other institutional investors own 83.71% of the company’s stock.
A number of equities analysts have issued reports on the stock. ValuEngine upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th. BidaskClub upgraded shares of ImmunoGen from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 14th. William Blair restated an “outperform” rating on shares of ImmunoGen in a research report on Monday, October 22nd. Zacks Investment Research cut shares of ImmunoGen from a “hold” rating to a “sell” rating in a research report on Thursday, August 2nd. Finally, HC Wainwright set a $18.00 price objective on shares of ImmunoGen and gave the company a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $14.75.
ImmunoGen (NASDAQ:IMGN) last announced its earnings results on Friday, November 2nd. The biotechnology company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. The firm had revenue of $10.90 million for the quarter, compared to analyst estimates of $13.60 million. ImmunoGen had a negative net margin of 176.35% and a negative return on equity of 1,182.18%. The company’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.61) EPS. Research analysts expect that ImmunoGen, Inc. will post -1.28 EPS for the current year.
In other news, VP Anna Berkenblit sold 5,851 shares of ImmunoGen stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $9.46, for a total transaction of $55,350.46. Following the sale, the vice president now owns 138,620 shares of the company’s stock, valued at approximately $1,311,345.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.44% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Signition LP Takes Position in ImmunoGen, Inc. (IMGN)” was originally published by Week Herald and is the property of of Week Herald. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://weekherald.com/2018/11/07/signition-lp-takes-position-in-immunogen-inc-imgn.html.
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Featured Story: What is dollar cost averaging (DCA)?
Want to see what other hedge funds are holding IMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunoGen, Inc. (NASDAQ:IMGN).
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.